A protocol for phase II study investigating the safety and efficacy of TM5614 in combination with nivolumab in the treatment of unresectable malignant melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A protocol for phase II study investigating the safety and efficacy of TM5614 in combination with nivolumab in the treatment of unresectable malignant melanoma

Published:2021-12 Issue:12 Volume:2 Page:e0197
ISSN:2691-3895
Container-title:Medicine: Case Reports and Study Protocols
language:en
Short-container-title:

Author:

Fujimura Taku,Yoshino Koji,Kato Hiroshi,Fukushima Satoshi,Otsuka Atsushi,Matsushita Shigeto,Miyata Toshio,Amagai Ryo,Ohuchi Kentaro,Furudate Sadanori,Hashimoto Akira,Kambayashi Yumi,Fujisawa Yasuhiro

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Psychiatry and Mental health

Reference16 articles.

1. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N Engl J Med,2019

2. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

3. Treatment of advanced melanoma: past, present and future;Fujimura;Life (Basel),2020

4. Plasminogen activator inhibitor-1 regulates infiltration of macrophages into melanoma via phosphorylation of FAK-Tyr925;Thapa;Biochem Biophys Res Commun,2014

5. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade;Tseng;J Invest Dermatol,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP